Benign prostatic hyperplasia


Medical treatment with α1-adrenergic antagonists and phosphodiesterase type 5 inhibitors is aimed at relaxing the smooth muscle in the bladder neck, urethra and/or prostate to assist in the passage of urine; steroid 5α-reductase inhibitors shrink the prostate by blocking DHT synthesis. Benign prostatic hyperplasia (BPH) is a common disorder in ageing men in… (More)
DOI: 10.1038/nrdp.2016.32


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics